8 completed, 2 terminated, 1 unknown, 1 withdrawn. 12 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 8, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow amrubicin: new trials by email Literature Review of amrubicin trials Research Report on amrubicin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer Pembrolizumab plus amurubicin - Small Cell Lung Cancer Extensive Stage | Phase 2 | Unknown | Wakayama Medical University | 25 | 2017-08-01 | 2020-05-19 |
| A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy TAS-102, Amrubicin (Japan), Topotecan (Japan/Europe) - Small Cell Lung Cancer (SCLC) | Phase 2 | Terminated | Taiho Oncology, Inc. | 18 | 2013-07-01 | 2024-09-05 |
| Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma Amrubicin - Soft Tissue Sarcoma | Phase 2 | Completed | University of Utah | 24 | 2011-09-01 | 2017-04-17 |
| Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma Amrubicin, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 1 / Phase 2 | Completed | Michaela Liedtke | 14 | 2011-08-01 | 2018-09-18 |
| A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Amrubicin - Thymoma, Thymus Cancer | Phase 2 | Completed | Heather Wakelee | 33 | 2011-06-01 | 2019-04-16 |
| Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma Amrubicin - Bladder Cancer | Phase 2 | Terminated | Matthew Galsky | 22 | 2011-02-01 | 2018-04-23 |
| A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer Amrubicin, Carboplatin, Pegfilgrastim - Extensive-Stage Small Cell Lung Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 81 | 2009-12-01 | 2016-05-05 |
| Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer Amrubicin - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | SCRI Development Innovations, LLC | 78 | 2009-12-01 | 2022-05-03 |
| Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer Amrubicin, Cisplatin, Etoposide - Small Cell Lung Cancer | Phase 2 | Completed | Celgene | 99 | 2006-11-01 | 2019-11-19 |
| Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy Amrubicin - Small Cell Lung Cancer | Phase 2 | Completed | Celgene | 75 | 2006-11-01 | 2019-10-24 |
| Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy. Amrubicin, Topotecan - Small Cell Lung Cancer | Phase 2 | Completed | Celgene Corporation | 76 | 2006-04-01 | 2009-09-30 |
| Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer Amrubicin - Metastatic Breast Cancer | Phase 2 | Withdrawn | Celgene Corporation | 66 | 2008-09-23 |
Small Cell Lung Carcinoma (5) · Breast Neoplasms (2) · Multiple Myeloma (1) · Neoplasm Metastasis (1) · Sarcoma (1) · Thymoma (1) · Thymus Neoplasms (1) · Urinary Bladder Neoplasms (1)
Celgene (2) · Celgene Corporation (2) · SCRI Development Innovations, LLC (2) · Heather Wakelee (1) · Matthew Galsky (1) · Michaela Liedtke (1) · Taiho Oncology, Inc. (1) · University of Utah (1) · Wakayama Medical University (1)
United States (9) · Italy (2) · Japan (2) · Netherlands (2) · United Kingdom (2) · Belgium (1) · Germany (1) · Poland (1)
Richard S Ungerleider, MD (3) · David R Spigel, M.D. (1) · Denise A. Yardley, M.D. (1) · Giorgio Scagliotti, MD (1) · Heather A. Wakelee (1) · Hiroaki Akamatsu, M.D. (1) · Kaoru Kubota, MD, PhD (1) · Kazuhiko Nakagawa, M.D., Ph.D. (1) · Mary O'Brien, MD (1) · Matthew D Galsky, MD (1) · Michaela Liedtke (1) · Nobuyuki Katakami, M.D., Ph.D. (1)